These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
349 related articles for article (PubMed ID: 28690108)
1. Improving homing in T cell therapy. Vignali D; Kallikourdis M Cytokine Growth Factor Rev; 2017 Aug; 36():107-116. PubMed ID: 28690108 [TBL] [Abstract][Full Text] [Related]
2. Enhancing tumor T cell infiltration to enable cancer immunotherapy. Zhang J; Endres S; Kobold S Immunotherapy; 2019 Feb; 11(3):201-213. PubMed ID: 30730277 [TBL] [Abstract][Full Text] [Related]
3. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies. Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557 [TBL] [Abstract][Full Text] [Related]
4. Tailored chemokine receptor modification improves homing of adoptive therapy T cells in a spontaneous tumor model. Garetto S; Sardi C; Martini E; Roselli G; Morone D; Angioni R; Cianciotti BC; Trovato AE; Franchina DG; Castino GF; Vignali D; Erreni M; Marchesi F; Rumio C; Kallikourdis M Oncotarget; 2016 Jul; 7(28):43010-43026. PubMed ID: 27177227 [TBL] [Abstract][Full Text] [Related]
5. The next challenge in cancer immunotherapy: controlling T-cell traffic to the tumor. Abastado JP Cancer Res; 2012 May; 72(9):2159-61. PubMed ID: 22549945 [TBL] [Abstract][Full Text] [Related]
6. Regulation of cytotoxic T-Lymphocyte trafficking to tumors by chemoattractants: implications for immunotherapy. Sharma RK; Chheda ZS; Jala VR; Haribabu B Expert Rev Vaccines; 2015 Apr; 14(4):537-49. PubMed ID: 25482400 [TBL] [Abstract][Full Text] [Related]
7. Adoptive transfer of type 1 CTL mediates effective anti-central nervous system tumor response: critical roles of IFN-inducible protein-10. Nishimura F; Dusak JE; Eguchi J; Zhu X; Gambotto A; Storkus WJ; Okada H Cancer Res; 2006 Apr; 66(8):4478-87. PubMed ID: 16618775 [TBL] [Abstract][Full Text] [Related]
8. Obstacles to T cell migration in the tumor microenvironment. Nicolas-Boluda A; Donnadieu E Comp Immunol Microbiol Infect Dis; 2019 Apr; 63():22-30. PubMed ID: 30961814 [TBL] [Abstract][Full Text] [Related]
9. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nagarsheth N; Wicha MS; Zou W Nat Rev Immunol; 2017 Sep; 17(9):559-572. PubMed ID: 28555670 [TBL] [Abstract][Full Text] [Related]
10. Reversing chemokine/chemokine receptor mismatch to enhance the antitumor efficacy of CAR-T cells. Zhang PF; Wang C; Zhang L; Li Q Immunotherapy; 2022 Apr; 14(6):459-473. PubMed ID: 35232284 [TBL] [Abstract][Full Text] [Related]
11. An HSV-2 based oncolytic virus can function as an attractant to guide migration of adoptively transferred T cells to tumor sites. Fu X; Rivera A; Tao L; Zhang X Oncotarget; 2015 Jan; 6(2):902-14. PubMed ID: 25460506 [TBL] [Abstract][Full Text] [Related]
12. Adoptive cytotoxic T lymphocyte therapy triggers a counter-regulatory immunosuppressive mechanism via recruitment of myeloid-derived suppressor cells. Hosoi A; Matsushita H; Shimizu K; Fujii S; Ueha S; Abe J; Kurachi M; Maekawa R; Matsushima K; Kakimi K Int J Cancer; 2014 Apr; 134(8):1810-22. PubMed ID: 24150772 [TBL] [Abstract][Full Text] [Related]
13. Innate Immune Cells and Their Contribution to T-Cell-Based Immunotherapy. Ginefra P; Lorusso G; Vannini N Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32580431 [TBL] [Abstract][Full Text] [Related]
14. Naïve CD8(+) T cell derived tumor-specific cytotoxic effectors as a potential remedy for overcoming TGF-β immunosuppression in the tumor microenvironment. Nguyen HH; Kim T; Song SY; Park S; Cho HH; Jung SH; Ahn JS; Kim HJ; Lee JJ; Kim HO; Cho JH; Yang DH Sci Rep; 2016 Jun; 6():28208. PubMed ID: 27306834 [TBL] [Abstract][Full Text] [Related]
15. Targeting the tumor and its associated stroma: One and one can make three in adoptive T cell therapy of solid tumors. Mondino A; Vella G; Icardi L Cytokine Growth Factor Rev; 2017 Aug; 36():57-65. PubMed ID: 28629762 [TBL] [Abstract][Full Text] [Related]
16. GMP production of anti-tumor cytotoxic T-cell lines for adoptive T-cell therapy in patients with solid neoplasia. Turin I; Pedrazzoli P; Tullio C; Montini E; La Grotteria MC; Schiavo R; Perotti C; Locatelli F; Carretto E; Maccario R; Siena S; Montagna D Cytotherapy; 2007; 9(5):499-507. PubMed ID: 17786611 [TBL] [Abstract][Full Text] [Related]
17. Cytokines and metabolic factors regulate tumoricidal T-cell function during cancer immunotherapy. Adler AJ; Mittal P; Ryan JM; Zhou B; Wasser JS; Vella AT Immunotherapy; 2017 Jan; 9(1):71-82. PubMed ID: 28000531 [TBL] [Abstract][Full Text] [Related]
18. Adoptively transferred human lung tumor specific cytotoxic T cells can control autologous tumor growth and shape tumor phenotype in a SCID mouse xenograft model. Oflazoglu E; Elliott M; Takita H; Ferrone S; Henderson RA; Repasky EA J Transl Med; 2007 Jun; 5():29. PubMed ID: 17592641 [TBL] [Abstract][Full Text] [Related]